News | May 27, 2026
Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Dual regulatory clearances for Sentire(R) Endoscopic surgical system strengthen the company’s expansion across Europe and Asia-Pacific in minimally invasive robotic surgery
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
